Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future
Zymeworks is strategically pivoting beyond its oncology focus with the $929 million acquisition of Theravance Biopharma, gaining the FDA-approved COPD therapy, Yupelri. This move aligns with current biopharma M&A trends emphasizing de-risked, cash-generating assets to address patent cliffs. While Yupelri offers stable revenue and long-term intellectual property, Zymeworks faces the challenge of integrating a respiratory asset into its existing clinical-stage oncology pipeline.
TBPH - Theravance Biopharma Inc Options
This article provides a detailed financial overview of Theravance Biopharma Inc. (TBPH), including its latest stock performance, market capitalization, key financial ratios, and insider/institutional ownership data. It presents various metrics such as P/E, sales growth, profit margins, and volatility, along with analyst recommendations and target prices. The data aims to give investors a comprehensive snapshot of the company's current financial health and market position.
TBPH SEC Filings - Theravance Bioph 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Theravance Biopharma (TBPH) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading forms. Recent filings detail equity grants to executives, a patent settlement for YUPELRI® extending generic availability to 2039, and the company's strategic restructuring and evaluation of alternatives following the ampreloxetine program wind-down, aiming to significantly reduce operating expenses. The detailed entries offer AI-generated summaries, impact scoring, and sentiment analysis for each filing.
TBPH - Theravance Biopharma Inc Short Interest
This article provides a detailed overview of Theravance Biopharma Inc (TBPH) stock, focusing on various financial metrics, short interest data, and performance indicators. It includes information on the company's market capitalization, income, sales, P/E ratio, short interest percentage, and analyst recommendations. The data presented covers fundamental, technical, and performance aspects of the stock.
TBPH - Theravance Biopharma Inc Latest SEC Filings
This article provides detailed financial data and performance metrics for Theravance Biopharma Inc (TBPH), including its latest stock close, market capitalization, income, sales, and various financial ratios. It also outlines insider ownership, institutional ownership, and short interest, along with price performance over different periods and analyst recommendations.
Funds tied to Eli Samaha trim Theravance Biopharma (TBPH) stake in open-market sales
Funds associated with Eli Samaha, managed by Madison Avenue Partners, LP, have significantly reduced their stake in Theravance Biopharma (TBPH) through open-market sales. Over three days, the funds sold a total of 336,697 shares at weighted average prices around $17 per share. Despite these sales, Madison Avenue Partners, LP entities still indirectly hold a substantial 9,174,453 shares of Theravance Biopharma common stock.
Zymeworks to acquire Theravance Biopharma in deal worth $929m
Zymeworks has announced its acquisition of Theravance Biopharma in a deal valued at approximately $929 million. This strategic move grants Zymeworks ownership of Yupelri, a key treatment for Chronic Obstructive Pulmonary Disease (COPD), broadening its portfolio. The acquisition aligns with Zymeworks' goal of diversifying its business through a combination of partner-driven cash flows and innovative R&D.
Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks
Arthur Cox advised Theravance Biopharma, Inc. on its definitive agreement to be acquired by Zymeworks Inc. for approximately US$929 million. The transaction values Theravance Biopharma at US$17.00 per share, plus a contingent value right for future proceeds from ampreloxetine. This acquisition, which follows a strategic review, is expected to close in the second half of 2026.
Zymeworks agrees to buy Theravance Biopharma for $929m
Canadian biotechnology company Zymeworks has signed an agreement to acquire Theravance Biopharma for approximately $929 million (C$1.32bn). Theravance Biopharma shareholders will receive $17 per share plus a contingent value right for 80% of net proceeds from future monetization of ampreloxetine. The deal, unanimously approved by both boards, is expected to close in the second half of 2026, pending shareholder and regulatory approvals.
Canadian Zymeworks acquires American Theravance Biopharma for $929 million
Canadian biotech company Zymeworks Inc. has agreed to acquire American Theravance Biopharma Inc. for $929 million, with the transaction expected to close in the second half of 2026. This acquisition supports Zymeworks' strategy to diversify its portfolio and optimize product value, including profiting from the sale of the Yupelri drug for chronic lung disease and acquiring Theravance's research and development assets.
Theravance Stock Down 3% After Zymeworks Announces Buyout
Theravance Biopharma's stock dropped 3% after announcing an all-cash acquisition by Zymeworks Inc. for approximately $929 million. The deal follows a strategic review by Theravance after its lead candidate, ampreloxetine, failed in a pivotal phase III study. Shareholders will receive $17.00 per share plus a contingent value right for 80% of future net proceeds from ampreloxetine's monetization.
After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion
Zymeworks is set to acquire Theravance Biopharma in a complex deal valued at less than $1 billion, marking the end of Theravance's three-decade legacy. Despite the sale, Theravance CEO Rick Winningham expressed ongoing commitment to creating impactful medicines. The acquisition highlights the dynamic and challenging nature of the biotechnology industry.
Zymeworks agrees to buy Theravance Biopharma for $929m
Canadian biotechnology company Zymeworks has reached an agreement to acquire Theravance Biopharma for approximately $929m in cash. Theravance Biopharma shareholders will receive $17 per share plus a contingent value right for 80% of future net proceeds from ampreloxetine, a drug for multiple system atrophy. The transaction is expected to close in the second half of 2026, pending shareholder and regulatory approvals.
Press Release: Zymeworks to Acquire Theravance Biopharma, Inc.
This press release announces Zymeworks' intent to acquire Theravance Biopharma, Inc. The acquisition is expected to create a stronger combined entity with an enhanced pipeline and capabilities. Further details about the terms of the acquisition and strategic rationale are anticipated in the full document.
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma
This article details two significant pharmaceutical acquisitions: Zymeworks' agreement to acquire Theravance Biopharma for approximately $929 million, primarily for its commercial COPD asset Yupelri and Irish tax attributes, and Ipsen's plan to acquire Kartos Therapeutics for up to $1.75 billion, adding the investigational MDM2 inhibitor navtemadlin to its oncology pipeline. Both deals aim to strengthen the acquirers' commercial portfolios and R&D pipelines, with Zymeworks focusing on profitability and Ipsen on late-stage oncology assets.
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks announced it will acquire Theravance Biopharma for $929 million in an all-cash transaction, expected to close in the second half of 2026. This acquisition will add Yupelri, a COPD treatment, to Zymeworks' commercial portfolio, giving it a 35% share of U.S. net profits from the drug. Zymeworks plans to finance the deal through a $350 million note, existing cash, and Theravance’s net cash balance, while also continuing its share repurchase program.
Zymeworks makes bold move with $929m Theravance Biopharma buy
Zymeworks has announced a $929 million acquisition of Theravance Biopharma, marking its entry into the respiratory disease sector. The deal centers on Yupelri, an FDA-approved COPD therapy, and is financed through a non-recourse arrangement, including a $350 million note and Theravance's cash balance. This strategic move aims to diversify Zymeworks' revenue, strengthen its financial position, and fund its oncology pipeline.
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders
Zymeworks is acquiring Theravance Biopharma for $929 million, with shareholders receiving $17.00 per share in cash and a contingent value right (CVR) for 80% of future net proceeds from ampreloxetine monetization. This deal, offering a 22% premium over Theravance's stock price on March 3, 2026, aims to provide significant value to shareholders despite the recent failure of a key Phase 3 study. The transaction is expected to close in the second half of 2026.
Theravance Biopharma to Be Acquired by Zymeworks for $17 Per Share Plus CVR
Theravance Biopharma (TBPH) has entered into an agreement to be acquired by Zymeworks for $17.00 per share in cash plus a contingent value right (CVR). The CVR entitles holders to additional cash based on net licensing proceeds, a $50 million milestone, and 10% of net sales for ampreloxetine. The deal is expected to close in the second half of 2026, subject to regulatory and shareholder approvals.
Zymeworks to acquire Theravance Biopharma for $929M
Zymeworks has agreed to acquire Theravance Biopharma for $17 per share in cash, valuing the company at approximately $929 million. Theravance shareholders will also receive a contingent value right for 80% of net proceeds from any ampreloxetine monetization over ten years. The transaction is expected to finalize in the latter half of 2026, pending customary closing conditions.
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
Theravance Biopharma has agreed to be acquired by Zymeworks for $17.00 per share in cash, totaling approximately $929 million. Additionally, Theravance Biopharma shareholders will receive a Contingent Value Right (CVR) entitling them to 80% of net proceeds from any future monetization of ampreloxetine over the next ten years. The transaction is expected to close in the second half of 2026, following a comprehensive strategic review by Theravance Biopharma's Board of Directors.
Zymeworks to Acquire Theravance Biopharma, Inc.
Zymeworks Inc. announced a definitive agreement to acquire Theravance Biopharma, Inc. for $17.00 per share, approximately $929 million. The acquisition will add YUPELRI® (revefenacin), a treatment for COPD, to Zymeworks' portfolio, anticipated to generate around $60 million in annualized cash flow. The transaction is structured with a $350 million non-recourse note from OMERS Life Sciences and Theravance's cash, with Zymeworks contributing $219 million.
Theravance Biopharma, Inc.(NasdaqGM:TBPH) added to Russell 2000 Value-Defensive Index
Theravance Biopharma, Inc. (NasdaqGM:TBPH) has been added to the Russell 2000 Value-Defensive Index. This news follows a series of recent announcements for the company, including its addition to the Russell 2000 Growth-Defensive Index, first-quarter earnings results, and various analyst rating adjustments. The article also provides a company profile and financial ratings.
Price to sales forward of Theravance Biopharma, Inc. – NASDAQ:TBPH
This article focuses on the "Price to sales forward" financial metric for Theravance Biopharma, Inc. (NASDAQ:TBPH). It briefly presents this data within the context of the company's financial information on TradingView. The content primarily provides navigation and structural elements typical of a financial data platform.
Price to book forward of Theravance Biopharma, Inc. – NASDAQ:TBPH
This article provides the "Price to book forward" value for Theravance Biopharma, Inc. (NASDAQ: TBPH). It indicates a specific period and market data source, highlighting it as financial information for investors. The article is a snippet of financial data from TradingView, focusing on key valuation metrics.
Enterprise value to revenue forward of Theravance Biopharma, Inc. – NASDAQ:TBPH
This article provides financial data for Theravance Biopharma, Inc. (NASDAQ: TBPH), specifically its enterprise value to revenue forward metric. The content appears to be a snapshot from a financial platform like TradingView, displaying the company's ticker, market status, and a navigation structure for various financial and community features.
Theravance Biopharma Inc Actuals & Estimates (NASDAQ:TBPH)
This article provides an overview of Theravance Biopharma, Inc. (NASDAQ: TBPH) financial actuals, analyst estimates, and stock performance data. It covers current stock price, market capitalization, historical highs and lows, future earnings expectations, and key financial metrics like revenue and EBITDA. The content also addresses frequently asked questions about investing in TBPH stock.
Enterprise value to EBIT forward of Theravance Biopharma, Inc. – NASDAQ:TBPH
This article provides the enterprise value to EBIT forward for Theravance Biopharma, Inc. (NASDAQ: TBPH). It indicates that the market was closed at the time of publication, with no trades executed. The information is presented within the context of financial data provided by TradingView, including various market data and reference data sources.
TBPH Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Theravance Biopharma, Inc. (TBPH) stock for 2027, based on analyst ratings. It includes current stock performance metrics, historical highs and lows, financial data like market capitalization, revenue, and earnings, and technical analysis ratings. The article also covers frequently asked questions about TBPH stock.
Form 8K Theravance Biopharma Inc For: 23 June By Investing.com
This article announces that Theravance Biopharma Inc. filed a Form 8K on June 23. It provides no further details about the content of the filing but lists the company's stock symbol (TBPH) and its performance on that day. The rest of the content includes market data, news headlines, and promotional material from Investing.com.
Form 4 Theravance Biopharma Inc For: 23 June By Investing.com
This article is a Form 4 filing for Theravance Biopharma Inc (TBPH) as reported by Investing.com, dated June 23, 2026, at 22:54. Form 4 filings are used to report changes in beneficial ownership of a company's securities by corporate insiders. The brief piece includes financial market data such as indices, commodities, bonds, and shares.
Form 4 Theravance Biopharma Inc For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Theravance Biopharma Inc on June 23. It notes that the company's stock symbol is TBPH, which saw a 2.48% increase. The article provides financial market data and news headlines, but no specific details from the Form 4 are included.
Theravance Biopharma (NASDAQ: TBPH) SVP awarded 18,750 Ordinary Shares
Theravance Biopharma's Senior Vice President, Aine Miller, was granted 18,750 Ordinary Shares on June 19, 2026. This award, valued at $0.0000 per share, represents a compensation-related grant rather than a market purchase. Following this transaction, Miller directly holds 196,084 Ordinary Shares of the company.
Theravance Biopharma (NASDAQ: TBPH) sets exit terms for Ireland SVP
Theravance Biopharma (NASDAQ: TBPH) announced that Dr. Áine Miller, Senior Vice President, Development and Head of its Ireland office, will depart on November 15, 2026, as part of a restructuring. Her exit package includes terms consistent with an amended employment contract, a $250,000 special pension contribution, and a grant of 18,750 restricted share units for her continued service until the termination date. This information was disclosed in an 8-K filing detailing the company's material event.
Form 8K Theravance Biopharma Inc For: 23 June By Investing.com
This article announces that Theravance Biopharma Inc. filed a Form 8K on June 23. This filing is a standard requirement for publicly traded companies to announce significant events that shareholders should know about. The article provides only this detail without further elaboration on the content of the 8K.
Theravance Biopharma Inc (TBPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Theravance Biopharma Inc (TBPH), detailing its current price momentum score as 9.32 and ranking it 36 out of 157 in the Pharmaceuticals industry. The analysis highlights key support and resistance levels for swing trading, presents readings from common technical indicators such as MACD, RSI, and Moving Averages, and offers a summary of buy and sell signals.
Theravance Biopharma SVP Rhonda Farnum sells $218,167 in shares By Investing.com
Rhonda Farnum, SVP of Communications & Medical Affairs at Theravance Biopharma (NASDAQ:TBPH), sold 13,314 shares totaling approximately $218,167 on June 15, 2026, via a pre-arranged trading plan. Despite the sale, TBPH shares have seen a 57% return over the past year, though InvestingPro analysis suggests they are slightly overvalued. The company recently reported strong Q4 results, including a non-GAAP net income of $3.1 million and robust Yupelri revenue, leading analysts like BTIG to reiterate a Buy rating.
Understanding Momentum Shifts in (TBPH)
This article analyzes Theravance Biopharma Inc. (NASDAQ: TBPH) using AI models, highlighting a neutral near and mid-term outlook but a long-term positive bias. It identifies a mid-channel oscillation pattern and offers three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss points. The analysis also provides multi-timeframe signal analysis, showing support and resistance levels.
Theravance Biopharma SVP Rhonda Farnum sells $218,167 in shares By Investing.com
Rhonda Farnum, SVP of Communications & Medical Affairs at Theravance Biopharma (NASDAQ:TBPH), sold 13,314 shares totaling $218,167 on June 15, 2026, as per a pre-arranged trading plan. This sale occurred while TBPH shares were trading at $16.71, reflecting a 57% return over the past year. The article also touches on the company's recent strong Q4 results for Yupelri and analyst ratings.
Theravance Biopharma SVP Rhonda Farnum sells $218,167 in shares By Investing.com
Rhonda Farnum, SVP of Communications & Medical Affairs at Theravance Biopharma (NASDAQ:TBPH), sold 13,314 ordinary shares worth approximately $218,167 on June 15, 2026, under a pre-arranged trading plan. Despite this insider sale, TBPH shares have seen a 57% return over the past year. The company recently reported strong Q4 results, including a non-GAAP net income of $3.1 million and Yupelri revenue of $70.6 million, leading analysts like BTIG to reiterate a Buy rating.
Insider Sell: Rhonda Farnum Sells Shares of Theravance Biopharma Inc (TBPH)
Rhonda Farnum, Senior Vice President of Commercial and Medical Affairs at Theravance Biopharma Inc (TBPH), sold 13,314 shares of the company on June 15, 2026. This transaction brings her total ownership to 232,457 shares. The stock is considered fairly valued with a price-to-GF-Value ratio of 0.92 and has seen no insider buys and seven insider sells over the past year.
Theravance Biopharma Inc (TBPH) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Theravance Biopharma Inc (TBPH), highlighting its current earnings forecast score of 7.33 within the Pharmaceuticals industry. Analysts have set an average price target of $27.00 for TBPH, with a "Buy" rating based on the consensus of 6 analysts. The report also details expected revenue for the next quarter at $21.80M and a forecasted EPS of $0.04.
Theravance Biopharma Inc (TBPH) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Theravance Biopharma Inc's (TBPH) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and shows no data for
Theravance Biopharma (TBPH) SVP Rhonda Farnum sells 13,314 shares at ~$16
Rhonda Farnum, Senior Vice President of Theravance Biopharma (TBPH), sold 13,314 ordinary shares of the company in three open-market transactions on June 15, 2026. The sales were conducted at weighted-average prices around $16.38 to $16.39 per share, totaling approximately $218,167, and were executed under a 10b5-1 plan. Following these sales, Farnum's direct holdings amount to 242,442 ordinary shares.
Theravance Biopharma Inc (TBPH) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Theravance Biopharma Inc (TBPH), listing its major shareholders by proportion, including Madison Avenue Partners LP and Weiss Asset Management. It also categorizes shareholders by type, such as Hedge Funds and Investment Advisors. Additionally, the report provides historical institutional shareholding data and recent shareholder activity with changes in holdings for key investors.
Theravance Biopharma Inc (TBPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Theravance Biopharma Inc (TBPH), focusing on its regional revenue contributions. As of the latest update, the company's revenue is primarily derived from the U.S. (69.76%) and Europe (30.24%). Data for business segments and profit contribution were not disclosed, and future fiscal year data (FY2024, FY2025) are also pending disclosure.
Theravance Biopharma (TBPH) director Susannah Gray receives new share and option grants
Theravance Biopharma (TBPH) director Susannah Gray received equity compensation on June 12, 2026, including 6,009 Ordinary Shares and a share option for 13,398 Ordinary Shares with an exercise price of $16.64. After these grants, she directly holds 48,146 Ordinary Shares. The option vests monthly over continuous service, with any remaining unvested portion vesting at the next annual shareholder meeting.
Director Dean J. Mitchell granted shares and options at Theravance (NASDAQ: TBPH)
Theravance Biopharma director Dean J. Mitchell received equity compensation, consisting of 6,009 ordinary shares and options for 13,398 ordinary shares. The options have an exercise price of $16.64 and vest monthly, with remaining unvested options vesting by the next annual shareholder meeting if service continues until then. Following these transactions, Mitchell directly holds 97,213 ordinary shares and options for 13,398 shares, with the options set to expire in June 2036.
Director at Theravance Biopharma (NASDAQ: TBPH) receives new share and option grants
Deepika Pakianathan, a director at Theravance Biopharma (NASDAQ: TBPH), recently received new equity compensation. On June 12, 2026, she acquired 6,009 Ordinary Shares and was granted a Share Option for 13,398 Ordinary Shares with an exercise price of $16.64. These transactions increased her direct holdings to 64,074 Ordinary Shares and provided options that vest monthly.
Director at Theravance Biopharma (TBPH) receives new share and option awards
Theravance Biopharma director Donal O'Connor received new equity awards, including 6,009 Ordinary Shares at no cost, increasing his holdings to 80,213 shares directly. He was also granted a share option for 13,398 Ordinary Shares with an exercise price of $16.64, expiring on June 11, 2036. The option vests monthly over time and any remaining unvested shares vest at the next annual shareholders' meeting, provided continuous service.
